Axsome Therapeutics Reports Third Quarter 2024 ... - Markets Insider

2 days ago · The net loss in the third quarter of 2024 reflects $40.9 million in non-cash charges, including a fair market value adjustment for contingent consideration of $16.4 million.

$40
OFF

Axsome Therapeutics Reports Third Quarter 2024 ... - Markets Insider

2 weeks from now

2 days ago · The net loss in the third quarter of 2024 reflects $40.9 million in non-cash charges, including a fair market value adjustment for contingent consideration of $16.4 million.

businessinsider.com

81%
OFF

Axsome Therapeutics’ Strong Q3 Growth Amidst ... - Markets Insider

2 weeks from now

2 days ago · The company reported impressive growth in its third-quarter 2024 financial results, achieving a total net product revenue of $104.8 million, marking an 81% increase year-over-year.

businessinsider.com

$1.34
OFF

Axsome Therapeutics: Strong Financial Performance And

2 weeks from now

2 days ago · Axsome Therapeutics reports Q3 EPS ($1.34), consensus ($1.41) ... Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update. ...

businessinsider.com

$40
OFF

Axsome Therapeutics Reports Third Quarter 2024 Financial

2 weeks from now

2 days ago · The net loss in the third quarter of 2024 reflects $40.9 million in non-cash charges, including a fair market value adjustment for contingent consideration of $16.4 million.

globenewswire.com

$40
OFF

Axsome Therapeutics Reports Third Quarter 2024 Financial Results …

2 weeks from now

2 days ago · The net loss in the third quarter of 2024 reflects $40.9 million in non-cash charges, including a fair market value adjustment for contingent consideration of $16.4 million.

yahoo.com

81%
OFF

Axsome Therapeutics Reports Third Quarter 2024 Financial Results …

2 weeks from now

2 days ago · Third Quarter 2024 Financial Highlights. Total net product revenue for the third quarter of 2024 was $104.8 million, representing 81% year-over-year growth. Total net product …

marketscreener.com

$125.00
OFF

Strong Q3 Performance And Promising Prospects Drive

2 weeks from now

2 days ago · In a report released today, Vikram Purohit from Morgan Stanley maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report), with a price target of $125.00. …

businessinsider.com

2%
OFF

New Jersey MarketBeats | US | Cushman & Wakefield

2 weeks from now

Oct 8, 2024 · Northern New Jersey's office vacancy rate climbed to 23.2% by the end of the third quarter of 2024, up 160 basis points year-over-year. ... MarketBeat reports analyze quarterly …

cushmanwakefield.com

00%
OFF

RFL - Rafael Holdings Inc Stock Price And Quote - FINVIZ.com

2 weeks from now

Market Cap: 49.38M: Forward P/E-EPS next Y-Insider Trans: 0.00%: Shs Float: 18.72M: Perf Month-14.10%: ... Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results …

finviz.com

$1.34
OFF

Axsome Therapeutics Reports Q3 EPS ($1.34), Consensus ($1.41)

2 weeks from now

3 days ago · Axsome Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update GlobeNewswire 4h Axsome Therapeutics reports Q3 EPS ($1.34), …

businessinsider.com

160%
OFF

Axsome Therapeutics Reports First Quarter 2024 ... - Markets Insider

2 weeks from now

May 6, 2024 · Total 1Q 2024 net product revenue of $75.0 million, representing 160% year-over-year growthAuvelity® 1Q 2024 net product sales of $53.4 million, r...

businessinsider.com

FAQs about Axsome Therapeutics Reports Third Quarter 2024 ... - Markets Insider Coupon?

What did Axsome Therapeutics do in Q3 2024?

NEW YORK, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today announced financial results for the third quarter of 2024 and provided a general business update. ...

Is Axsome Therapeutics a profitable company?

Summary Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m, up 81% YoY, but net loss increased to $(64.6m). Despite positive market response and promising pipeline candidates, Axsome's profitability remains distant, with significant cash burn and competition from pharma giants. ...

What did Axsome Therapeutics do in the first quarter?

“The first quarter was marked by strong financial performance for our on-market products which are delivering important and differentiated treatment options for patients living with depression, narcolepsy and obstructive sleep apnea,” said Herriot Tabuteau, MD, CEO of Axsome Therapeutics. ...

Should I Sell Axsome Therapeutics (axsm) stock on a price spike?

Terms Of Use Privacy Do Not Sell My Personal Information Market Data Sources Axsome Therapeutics' Q3 2024 earnings report shows a revenue beat with $104.8m. See why I think selling AXSM stock on any price spike is recommended. ...

Should you buy Axsome Therapeutics (Axsome)?

Ami Fadia has given his Buy rating due to a combination of factors that indicate strong performance and potential for Axsome Therapeutics. The company’s third-quarter revenue surpassed expectations, driven largely by Auvelity sales, which were significantly higher than consensus estimates. ...

Who is Axsome Therapeutics (axsm)?

Begin your TipRanks Premium journey today. Axsome Therapeutics (AXSM) Company Description: Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel therapies for the management of central nervous system disorders. ...